PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
- Conditions
- Diabetes MellitusObesity
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 902
- Registration Number
- NCT05579977
- Locations
- 🇨🇦
LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada
🇺🇸San Fernando Valley Health Institute, Canoga Park, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 94
- Registration Number
- NCT05580003
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇧🇪Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: patterns of use of combination therapy and monotherapy
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05576051
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT05573555
- Locations
- 🇺🇸
Moffitt McKinley Hospital, Tampa, Florida, United States
🇺🇸Stanford Women's Cancer Center, Palo Alto, California, United States
🇺🇸UCSF Medical Center at Mission Bay, San Francisco, California, United States
Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05572567
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- Conditions
- Hemophilia BHemophilia A
- Interventions
- Diagnostic Test: Testing of hepatic AAV Vector integration
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 263
- Registration Number
- NCT05568719
- Locations
- 🇺🇸
UC Davis Health, Sacramento, California, United States
🇺🇸UC Davis Ambulatory Care Clinic, Sacramento, California, United States
🇺🇸UC Davis Hemophilia Treatment Center, Sacramento, California, United States
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7
- Registration Number
- NCT05567887
- Locations
- 🇯🇵
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, Japan
🇯🇵Yamagata University Hospital, Yamagata, Japan
🇯🇵Japanese Foundation for Cancer Research, Koto, Tokyo, Japan
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 436
- Registration Number
- NCT05567952
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
🇺🇸Mercury Street Medical Group, PLLC, Butte, Montana, United States
🇺🇸Global Health Clinical Trials, Miami, Florida, United States
A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT05568407
- Locations
- 🇧🇷
Hospital Moinhos de Vento, Porto Alegre, RIO Grande DO SUL, Brazil
🇧🇷Hospital Mãe de Deus/Aesc, Porto Alegre, RIO Grande DO SUL, Brazil
🇧🇷Hospital Alemão Oswaldo Cruz, Sao Paulo, SP, Brazil
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 508
- Registration Number
- NCT05565391
- Locations
- 🇺🇸
Pfizer, New York, New York, United States